As of Jan 19
| 0.00 / 0.00%|
The 8 analysts offering 12-month price forecasts for Supernus Pharmaceuticals Inc have a median target of 50.50, with a high estimate of 61.00 and a low estimate of 40.00. The median estimate represents a +7.68% increase from the last price of 46.90.
The current consensus among 8 polled investment analysts is to Buy stock in Supernus Pharmaceuticals Inc. This rating has held steady since January, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.